Article
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Review Reveals the Hidden Burden of Psoriasis on Children, Families
Psoriasis as an Inflammatory Disease, and What’s Changed Over Time
Real-World Data Show 12-Month Drug Survival Rates Among Anti-TNF Biosimilars in Psoriasis, PsA
Infection Risk Higher in HS Compared With Psoriasis With Adalimumab
The Totality of Evidence of Ustekinumab Biosimilar SB17
Beyond the Surface: How New Therapies, Patient-Centered Care Are Changing Psoriasis Outcomes